|
HINT1
|
histidine triad nucleotide binding protein 1 |
- Regulation of MITF-M-dependent genes involved in apoptosis
- Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
- Transcriptional and post-translational regulation of MITF-M expression and activity
|
- Adenosine phosphate
- Guanosine-5'-Monophosphate
- 5'-O-(N-Ethyl-Sulfamoyl)Adenosine
- Adenosine-5'-ditungstate
- 8-Bromo-Adenosine-5'-Monophosphate
|
|
|
HSH2D
|
hematopoietic SH2 domain containing |
|
|
|
|
HSPA1A
|
heat shock protein family A (Hsp70) member 1A |
- Viral RNP Complexes in the Host Cell Nucleus
- Regulation of HSF1-mediated heat shock response
- HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
- Attenuation phase
- HSF1-dependent transactivation
- AUF1 (hnRNP D0) binds and destabilizes mRNA
- Neutrophil degranulation
- PKR-mediated signaling
- Mitochondrial unfolded protein response (UPRmt)
- Regulation of HSF1-mediated heat shock response
- HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
- Attenuation phase
- HSF1-dependent transactivation
- Neutrophil degranulation
- PKR-mediated signaling
- Mitochondrial unfolded protein response (UPRmt)
|
|
|
|
HSPA8
|
heat shock protein family A (Hsp70) member 8 |
- Regulation of HSF1-mediated heat shock response
- HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
- Attenuation phase
- HSF1-dependent transactivation
- Lysosome Vesicle Biogenesis
- Golgi Associated Vesicle Biogenesis
- CHL1 interactions
- AUF1 (hnRNP D0) binds and destabilizes mRNA
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- mRNA Splicing - Major Pathway
- Clathrin-mediated endocytosis
- Protein methylation
- GABA synthesis, release, reuptake and degradation
- Lipophagy
- Chaperone Mediated Autophagy
- Late endosomal microautophagy
- Respiratory syncytial virus genome transcription
- PKR-mediated signaling
|
- Dasatinib
- (2R,3R,4S,5R)-2-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
- Copper
- Artenimol
|
|
|
IL6ST
|
interleukin 6 cytokine family signal transducer |
- Interleukin-6 signaling
- Interleukin-6 signaling
- IL-6-type cytokine receptor ligand interactions
- Interleukin-35 Signalling
- Interleukin-27 signaling
- Interleukin-27 signaling
|
|
|
|
ILKAP
|
ILK associated serine/threonine phosphatase |
|
|
|
|
INPPL1
|
inositol polyphosphate phosphatase like 1 |
- Synthesis of PIPs at the plasma membrane
- Synthesis of IP3 and IP4 in the cytosol
- Interleukin receptor SHC signaling
- Signaling by CSF1 (M-CSF) in myeloid cells
|
|
|
|
IRF2BP2
|
interferon regulatory factor 2 binding protein 2 |
|
|
|
|
ITK
|
IL2 inducible T cell kinase |
- Generation of second messenger molecules
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
|
- Staurosporine
- Pazopanib
- Fostamatinib
- Zanubrutinib
|
|
|
JAK2
|
Janus kinase 2 |
- Interleukin-6 signaling
- Interleukin-6 signaling
- MAPK3 (ERK1) activation
- MAPK1 (ERK2) activation
- Prolactin receptor signaling
- Prolactin receptor signaling
- Signaling by SCF-KIT
- Signaling by Leptin
- RMTs methylate histone arginines
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RAF activation
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- IL-6-type cytokine receptor ligand interactions
- Signaling by moderate kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Cyclin D associated events in G1
- Interferon gamma signaling
- Regulation of IFNG signaling
- Regulation of IFNG signaling
- Interleukin-20 family signaling
- Interleukin-35 Signalling
- Signaling by Erythropoietin
- Signaling by Erythropoietin
- Interleukin-12 signaling
- Interleukin-12 signaling
- Interleukin-23 signaling
- Interleukin-23 signaling
- Interleukin-27 signaling
- Interleukin-27 signaling
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phospholipase C gamma (PLCG)
- Erythropoietin activates STAT5
- Erythropoietin activates RAS
- Erythropoietin activates RAS
- Interleukin receptor SHC signaling
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Potential therapeutics for SARS
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
- IFNG signaling activates MAPKs
- Growth hormone receptor signaling
- Growth hormone receptor signaling
- Factors involved in megakaryocyte development and platelet production
|
- 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
- XL019
- 5-phenyl-1H-indazol-3-amine
- 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide
- 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
- Ruxolitinib
- Tofacitinib
- Pacritinib
- Baricitinib
- Entrectinib
- Fostamatinib
- Fedratinib
- Abrocitinib
- Zanubrutinib
- Pralsetinib
|
|
|
JAK3
|
Janus kinase 3 |
- Interleukin-7 signaling
- Interleukin-7 signaling
- Signaling by ALK
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- Interleukin-20 family signaling
- Interleukin-15 signaling
- Interleukin-15 signaling
- Interleukin-9 signaling
- Interleukin-2 signaling
- Interleukin-21 signaling
- Interleukin receptor SHC signaling
- Potential therapeutics for SARS
|
- 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
- R-348
- Ruxolitinib
- Tofacitinib
- Baricitinib
- Fostamatinib
- Abrocitinib
- Zanubrutinib
|
- T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
|
|
JUP
|
junction plakoglobin |
- Adherens junctions interactions
- VEGFR2 mediated vascular permeability
- Neutrophil degranulation
- Keratinization
- Formation of the cornified envelope
- RHOA GTPase cycle
- RHOB GTPase cycle
- RHOC GTPase cycle
- CDC42 GTPase cycle
- RHOQ GTPase cycle
- RHOH GTPase cycle
- RHOJ GTPase cycle
- Regulation of CDH11 function
- Regulation of CDH11 function
- Regulation of CDH19 Expression and Function
- Regulation of CDH1 Function
- Degradation of CDH1
- Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
- CDH11 homotypic and heterotypic interactions
|
|
- Naxos disease and Carvajal syndrome
- Arrhythmogenic right ventricular cardiomyopathy (ARVC)
|
|
LAMTOR2
|
late endosomal/lysosomal adaptor, MAPK and MTOR activator 2 |
- Macroautophagy
- MTOR signalling
- mTORC1-mediated signalling
- Energy dependent regulation of mTOR by LKB1-AMPK
- TP53 Regulates Metabolic Genes
- MAP2K and MAPK activation
- Neutrophil degranulation
- Regulation of PTEN gene transcription
- Amino acids regulate mTORC1
|
|
|
|
LBHD1
|
LBH domain containing 1 |
|
|
|
|
LCK
|
LCK proto-oncogene, Src family tyrosine kinase |
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Nef and signal transduction
- Nef Mediated CD4 Down-regulation
- Downstream TCR signaling
- Phosphorylation of CD3 and TCR zeta chains
- Translocation of ZAP-70 to Immunological synapse
- Generation of second messenger molecules
- PECAM1 interactions
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- DAP12 signaling
- Co-stimulation by CD28
- CD28 dependent PI3K/Akt signaling
- CD28 dependent Vav1 pathway
- Co-inhibition by CTLA4
- Co-inhibition by PD-1
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- RHOH GTPase cycle
- Interleukin-2 signaling
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- FLT3 signaling through SRC family kinases
|
- Dasatinib
- AP-22408
- Staurosporine
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- {4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid
- Phosphoaminophosphonic Acid-Adenylate Ester
- 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
- 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
- 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
- N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
- N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
- N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
- Ponatinib
- Nintedanib
- Fostamatinib
- Zanubrutinib
- Zotiraciclib
|
- Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
|
|
LCP2
|
lymphocyte cytosolic protein 2 |
- GPVI-mediated activation cascade
- Generation of second messenger molecules
- Generation of second messenger molecules
- DAP12 signaling
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
|
|
|
|
LRRC7
|
leucine rich repeat containing 7 |
|
|
|
|
LYN
|
LYN proto-oncogene, Src family tyrosine kinase |
- GPVI-mediated activation cascade
- Signaling by SCF-KIT
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Cell surface interactions at the vascular wall
- FCGR activation
- PECAM1 interactions
- Fc epsilon receptor (FCERI) signaling
- Fc epsilon receptor (FCERI) signaling
- EPH-Ephrin signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Role of LAT2/NTAL/LAB on calcium mobilization
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- FCERI mediated NF-kB activation
- Co-stimulation by CD28
- Co-inhibition by CTLA4
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- EPHA-mediated growth cone collapse
- EPHA-mediated growth cone collapse
- EPH-ephrin mediated repulsion of cells
- Dectin-2 family
- CD209 (DC-SIGN) signaling
- CD22 mediated BCR regulation
- Cyclin D associated events in G1
- Platelet Adhesion to exposed collagen
- Signaling by Erythropoietin
- Signaling by Erythropoietin
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phospholipase C gamma (PLCG)
- Erythropoietin activates STAT5
- Erythropoietin activates RAS
- Erythropoietin activates RAS
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- FCGR3A-mediated IL10 synthesis
- FCGR3A-mediated phagocytosis
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Signaling by CSF1 (M-CSF) in myeloid cells
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
- Growth hormone receptor signaling
- Growth hormone receptor signaling
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
- Dasatinib
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- Bosutinib
- Ponatinib
- Nintedanib
- Fostamatinib
|
|
|
MAP1B
|
microtubule associated protein 1B |
|
|
|
|
MATK
|
megakaryocyte-associated tyrosine kinase |
- Downregulation of ERBB2 signaling
|
|
|